An exploration of LAF‐bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non—small cell lung cancer

BACKGROUND: Immune checkpoint inhibitor (ICI) combined with chemotherapy is one of the standards of care for advanced non–small cell lung cancer (NSCLC) without driver mutations. However, the biomarker of combination therapy is still unknown. Although previous studies have confirmed that low allele...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shuyang, Yang, Lu, Yang, Yaning, Xin, Ying, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715764/
https://www.ncbi.nlm.nih.gov/pubmed/36274215
http://dx.doi.org/10.1111/1759-7714.14696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715764/
https://www.ncbi.nlm.nih.gov/pubmed/36274215
http://dx.doi.org/10.1111/1759-7714.14696

Ejemplares similares